BioDelivery Sciences International Inc. (NASDAQ:BDSI) received a $6.00 price target from Roth Capital in a research note issued on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price target would suggest a potential upside of 258.21% from the company’s current price.

A number of other equities research analysts also recently commented on BDSI. Piper Jaffray Cos. reaffirmed a “sell” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. FBR & Co reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 20th. Janney Montgomery Scott raised BioDelivery Sciences International from a “neutral” rating to a “buy” rating and upped their target price for the stock from $2.45 to $4.00 in a research report on Friday, September 23rd. Finally, Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $6.43.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) traded down 2.94% during trading on Monday, reaching $1.65. The company had a trading volume of 238,554 shares. The company’s market capitalization is $89.29 million. The firm’s 50 day moving average is $2.13 and its 200-day moving average is $2.37. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $6.23.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.04. The company earned $3.60 million during the quarter, compared to analyst estimates of $3.58 million. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. The business’s revenue was up 200.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.39) earnings per share. On average, equities analysts expect that BioDelivery Sciences International will post ($1.23) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/biodelivery-sciences-international-inc-bdsi-pt-set-at-6-00-by-roth-capital.html.

In other news, Director Francis E. Odonnell, Jr. sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $2.57, for a total transaction of $257,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Paolantonio Ernest Robert De sold 14,800 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $2.44, for a total value of $36,112.00. Following the transaction, the chief financial officer now directly owns 14,866 shares of the company’s stock, valued at $36,273.04. The disclosure for this sale can be found here. Company insiders own 9.00% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP acquired a new position in shares of BioDelivery Sciences International during the third quarter worth about $567,000. KCG Holdings Inc. increased its position in BioDelivery Sciences International by 235.8% in the third quarter. KCG Holdings Inc. now owns 39,347 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 27,630 shares during the last quarter. Morgan Stanley increased its position in BioDelivery Sciences International by 226.0% in the third quarter. Morgan Stanley now owns 302,859 shares of the specialty pharmaceutical company’s stock valued at $818,000 after buying an additional 209,967 shares during the last quarter. Tiverton Asset Management LLC increased its position in BioDelivery Sciences International by 206.1% in the third quarter. Tiverton Asset Management LLC now owns 180,417 shares of the specialty pharmaceutical company’s stock valued at $487,000 after buying an additional 121,468 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in BioDelivery Sciences International by 91.1% in the third quarter. Ameriprise Financial Inc. now owns 1,703,357 shares of the specialty pharmaceutical company’s stock valued at $4,599,000 after buying an additional 812,089 shares during the last quarter. 51.28% of the stock is owned by institutional investors and hedge funds.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.